FCM marker importance for MRD assessment in T-Cell Acute Lymphoblastic Leukemia: An AIEOP-BFM-ALL-FLOW Study Group Report.
Florian KowarschMargarita Maurer-GranofszkyLisa WeijlerMatthias WödlingerMichael ReiterAngela SchumichTamar FeuersteinSimona SalaMichaela NovakovaGiovanni FagginGiuseppe GaipaOndrej HrusakBarbara BuldiniMichael N DworzakPublished in: Cytometry. Part A : the journal of the International Society for Analytical Cytology (2023)
Based on the available limited set tested (CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99), our findings prove that CD48 and CD99 are useful markers for minimal residual disease (MRD) monitoring in T-ALL. The proposed pipeline can be applied for evaluation of other marker combinations in the future. This article is protected by copyright. All rights reserved.